Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
52 /100
HIGH RISK
Score updated Oct 13, 2026

GRCE — Grace Therapeutics, Inc. Dilution Risk Tracker

Track GRCE dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track GRCE — Get alerts when the score changes →

As of October 13, 2026, Grace Therapeutics, Inc. (GRCE) has a DilutionWatch DilutionScore of 52/100, rated HIGH dilution risk. Grace Therapeutics, Inc. has a market capitalization of $42.49M, 21.04M shares outstanding, 35 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
52
💰 Cash Runway
65
📊 Float Risk
30
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 7%
💰 Capital Raise model 15%
• Under 12 months cash (11mo)
🔔 Track GRCE — Get forecast alerts →

Market Data

Market Cap$42.49M
Shares Outstanding21.04M
Float12.79M
Cash$13.77M
DebtN/A
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore52/100DilutionWatch score record
Shares Outstanding21.04MVerified float table or market cache
Public Float12.79MVerified float table or market cache
Market Cap$42.49MMarket data cache
Cash Runway11.1 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 6.

Recent SEC source mix: 4 5, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↓ 12.0% shares (2026Q1 vs prior)
35 institutional holders · 4.81M shares
#1 Cerity Partners LLC 849.1K shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 803.3K shares
#3 Eversept Partners, LP 756.6K shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest1.72M
Days to Cover19.0
% of Float13.4%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-06-18
4 INSIDER TRANSACTION 2026-10-05
4 INSIDER TRANSACTION 2026-10-01
4 INSIDER TRANSACTION 2026-09-23
4 INSIDER TRANSACTION 2026-09-21
Full SEC filing analysis available with free account →

Recent News

Factual GRCE Dilution Snapshot

Grace Therapeutics, Inc. (GRCE) has a DilutionScore of 52/100, rated High dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

GRCE's DilutionScore is currently 52/100 (High risk), with 2 score changes tracked over 89 days. The score improved from 49/100 (Medium risk).

Period Score Risk Level Duration
Aug 26 – Oct 13, 202652/100HIGH49 days
Aug 22 – Aug 25, 202649/100MEDIUM4 days
Jul 16 – Aug 21, 202642/100MEDIUM36 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

GRCE shares outstanding have decreased 0.0% from 15.47M (May 2026) to 15.47M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 19, 202615.47M12.79M▲ 10.14%
May 08, 202615.47M11.61M▲ 8.72%
May 01, 202615.47M10.68M▲ 9.28%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track GRCE Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment GRCE files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking GRCE — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for GRCE
GRCE FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.